Correction of a murine model of von Willebrand disease by gene transfer

Blood

Volumn 108, Issue 3, 2006, Pages 862-869

  Pergolizzi, Robert G ^a   Jin, Guangchun ^a   Chan, Diane ^a   Pierre, Lorraine ^a   Bussel, James ^a   Ferris, Barbara ^a   Leopold, Philip L ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BOTROCETIN; COMPLEMENTARY DNA; RNA; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE TRANSFER; HEMOSTASIS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; WESTERN BLOTTING; WILD TYPE;

EID: 33746661500     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2330     Document Type: Article

References (43)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69:454-459.
2. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123:893-898.
3. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997;76:1-20.
4. Mohlke KL, Nichols WC, Ginsburg D. The molecular basis of von Willebrand disease. Int J Clin Lab Res. 1999;29:1-7.
5. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351:683-694.
6. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191.
7. Johns Hopkins University. Von Willebrand disease. OMIM: online Mendelian inheritance in man. Available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim. Accessed May 26, 2005.
8. Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol. 1997;29:91-105.
9. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
10. Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973;52:2708-2716.
11. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
12. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95:9524-9529.
13. Sadler JE. Von Willebrand disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill; 1989:2171-2187.
14. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52:2757-2764.
15. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A. 1974;71:1906-1909.
16. Nachman R, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest. 1977;60:914-921.
17. Murine VWF cDNA Sequence. Available at: http://www.sheffield.ac.uk/vwf/ murinecdna.html. Accessed May 13, 2006.
18. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982;95:355-360.
19. Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost. 2004;2:257-265.
20. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor: studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60:390-404.
21. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991;266:21948-21955.
22. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101:613-624.
23. Haberichter SL, Fahs SA, Montgomery RR. von Willebrand factor storage and multimerization: two independent intracellular processes. Blood. 2000;96:1808-1817.
24. Menache D. Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2. Haemophilia. 1998;4(suppl 3):44-47.
25. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10:689-697.
26. Denis CV, Wagner DD. Insights from von Willebrand disease animal models. Cell Mol Life Sci. 1999;56:977-990.
27. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6:1258-1266.
28. Zhang G, Gao X, Song YK, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther. 2004;11:675-682.
29. Krizek DR, Rick ME. A rapid method to visualize von Willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res. 2000;97:457-462.
30. Rathore V, Stapleton MA, Hillery CA, et al. PECAM-1 negatively regulates GPIb/V/IX signaling in murine platelets. Blood. 2003;102:3658-3664.
31. Rathore V, Wang D, Newman DK, Newman PJ. Phospholipase Cγ2 contributes to stable thrombus formation on VWF. FEBS Lett. 2004;573:26-30.
32. Chuah MK, Schiedner G, Thorrez L, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood. 2003;101:1734-1743.
33. Barrowcliffe TW. Standardization of FVIII and FIX assays. Haemophilia. 2003;9:397-402.
34. Hubbard AR, Heath AB. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost. 2004;2:1380-1384.
35. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70.
36. Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3:695-702.
37. Furlan M. von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72:341-348.
38. Fukuda K, Doggett T, Laurenzi IJ, Liddington RC, Diacovo TG. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol. 2005;12:152-159.
39. Liu J, Pestina TI, Berndt MC, Steward SA, Jackson CW, Gartner TK. The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets. J Thromb Haemost. 2004;2:2213-2222.
40. Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A. 1985;82:8752-8756.
41. Ewenstein BM. von Willebrand's disease. Annu Rev Med. 1997;48:525-542.
42. Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood. 1997;90:3555-3567.
43. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115: 2752-2761.